Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Treatment outcomes after intraluminal brachytherapy following definitive chemoradiotherapy in patients with esophageal cancer.
[esophageal carcinoma]
To
report
the
results
of
treatment
with
intraluminal
brachytherapy
(
ILRT
)
after
concurrent
chemoradiotherapy
for
esophageal
carcinoma
with
respect
to
disease
free
survival
(
DFS
)
,
dysphagia
free
interval
(
DFI
)
,
and
complications
of
treatment
.
The
study
retrospectively
analyzed
the
records
of
26
eligible
patients
with
nonmetastatic
carcinoma
of
the
esophagus
treated
with
definitive
chemoradiotherapy
followed
by
ILRT
between
2008
and
2011
.
The
DFS
and
DFI
were
estimated
and
factors
likely
to
influence
them
were
analyzed
.
Nineteen
(
73
%
)
patients
were
males
.
The
mean
age
at
presentation
was
60
years
(
range
:
47
-
90
years
)
.
All
the
patients
had
squamous
cell
carcinomas
.
Following
treatment
,
the
median
DFS
was
12
.
7
months
(
range
:
0
-
27
months
)
.
Sixteen
patients
(
61
.
5
%
)
had
local
control
of
their
disease
,
while
one
had
residual
disease
at
completion
of
treatment
.
Other
than
three
patients
who
were
not
evaluated
for
recurrent
dysphagia
,
six
(
23
.
1
%
)
had
proven
local
recurrence
on
follow-up
.
The
estimated
mean
DFI
was
13
.
8
months
(
range
:
0
-
27
months
)
.
One
patient
died
of
tracheoesophageal
fistula
following
treatment
.
On
statistical
analysis
,
only
the
location
of
tumor
was
prognostically
significant
,
with
lower
third
tumors
performing
worse
.
Other
probable
predictors
of
poor
outcome
included
large
volume
(
>
40
cc
)
,
tumor
length
(
>
6
cm
)
,
and
eccentric
location
.
ILRT
boost
following
concurrent
chemoradiotherapy
is
well
tolerated
and
potentially
improves
outcomes
.
It
might
be
beneficial
in
selected
patients
with
esophageal
carcinoma
.
Further
studies
are
required
to
identify
its
role
in
definitive
treatment
.
Diseases
Validation
Diseases presenting
"dysphagia"
symptom
alexander disease
cadasil
cushing syndrome
dedifferentiated liposarcoma
dystrophic epidermolysis bullosa
epidermolysis bullosa simplex
esophageal adenocarcinoma
esophageal carcinoma
esophageal squamous cell carcinoma
familial hypocalciuric hypercalcemia
inclusion body myositis
kindler syndrome
liposarcoma
locked-in syndrome
neuralgic amyotrophy
oligodontia
triple a syndrome
well-differentiated liposarcoma
This symptom has already been validated